RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis

Cancer Research

Volumn 67, Issue 22, 2007, Pages 10849-10858

  Blackburn, Jessica S ^a   Rhodes, C Harker ^b   Coon, Charles I ^a   Brinckerhoff, Constance E ^a,c  

^a NORRIS COTTON CANCER CENTER   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE 3; RNA;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PREVENTION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANIMALS; CELL LINE, TUMOR; COLLAGENASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG; MATRIX METALLOPROTEINASE 1; MELANOMA; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 36348950448     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1791     Document Type: Article

References (38)

1. Balch C, Soong S-J, Atkins M, Buzaid A, Thompson J. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004;54:131-49.
2. Leiter U, Friedegund M, Shittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol 2004;86:172-8.
3. Gogas H, Kirkwood J, Sondak V. Chemotherapy for metastatic melanoma. Cancer 2007;109:455-64.
4. Uribe P, Andrade L, Gonzalez S. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol 2006;126:161-6.
5. Lopez-Bergami P, Huang C, Goydos J, et al. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 2007;11:447-60.
6. Jorgensen K, Holm R, Maelandsmo G, Florenes V. Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome. Clin Cancer Res 2003;9:5325-31.
7. Satyamoorthy K, Li G, Gerrero M, et al. Constitutive MAPK activation in melanoma is mediated by both BRAF mutation and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
8. Sharma A, Tran M, Liang S, et al. Targeting MAPK/ERK in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastasis. Cancer Res 2006;66:8200-9.
9. Kolch W, Kotwaliwale A, Vass K, Janosch P. The role of Raf kinases in malignant transformation. Exp Rev Mol Med 2002;25:1-18.
10. Huntington JT, Shields JM, Der CJ, et al. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells. J Bio Chem 2004;279:33168-76.
11. Park CH, Lee MJ, Ahn J, et al. Heat shock-induced matrix metalloproteinase (MMP)-1 and MMP-3 are mediated through ERK and JNK activation and via an autocrine interleukin-6 loop. J Invest Dermatol 2004;123:1012-9.
12. Page-McCaw A, Ewald A, Werb Z. Matrix metalloproteinases and the regulation of tissue remodeling. Nat Rev Mol Cell Biol 2007;8:221-33.
13. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003;200:448-64.
14. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000;36:1621-30.
15. Yoon S-O, Park S-J, Yun C-H, Chung A-S. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003;36:128-37.
16. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 2006;11:479-91.
17. Walker R, Wooley DE. Immunolocalisation studies of matrix metalloproteinases-1, -2 and -3 in human melanoma. Virchows Arch 1999;435:574-9.
18. Airola K, Karonen T, Vaalamo M, et al. Expression of collagenase-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999;80:733-43.
19. Kurschat P, Wickenhauser C, Groth W, Krieg T, Mauch C. Identification of activated MMP-2 as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J Pathol 2002;197:179-87.
20. Hofmann U, Westphal J, Was E, et al. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated MMP-2 correlates with melanoma progression. Br J Cancer 1999;81:774-82.
21. Benbow U, Schoenermark M, Mitchell T, et al. A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen. J Bio Chem 1999;274:25371-8.
22. Durko M, Navab R, Shibata H, Brodt P. Suppression of basement membrane type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1. Biochim Biophys Acta 1998;1356:271-80.
23. Iida J, McCarthy J. Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-β. Melanoma Res 2007;17:205-13.
24. Wyatt CA, Geoghegan JC, Brinckerhoff CE. Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix destruction and tumor growth. Cancer Res 2005;65:11101-8.
25. Meier F, Nesbit M, Hsu M, Martin B, Donatien P, Herlyn M. Human melanoma progression in skin reconstructs: biological significance of bFGF. Am J Pathol 2000;156:193-200.
26. Nicklas J, Buel E. Development of an Alu-based, real-time PCR method for quantitation of human DNA in forensic samples. J Forensic Sci 2003;48:1-9.
27. Ntayi C, Lorimier S, Berthier-Vergnes O, Hornebeck W, Bernard P. Cumulative influence of matrix metalloproteinase-1 and -2 in the migration of melanoma cells within three-dimensional type I collagen lattices. Exp Cell Res 2001;270:110-8.
28. Hass T, Madri J. Extracellular matrix driven matrix metalloproteinase production in endothelial cells. Trends Cardiovasc Med 1999;9:70-7.
29. Handsley M, Edwards D. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005;115:849-60.
30. Demikesesn C, Buyukpinarbasili N, Ramazanoglu R, Oguz O, Mandel N, Kaner G. The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of VEGF and bFGF. Pathology 2006;38:132-7.
31. Staton C, Stibbling S, Tazzyman S, Hughes R, Brown N, Lewis C. Current methods for assaying angiogenesis in vitro and in vivo. Int J Exp Pathol 2004;85:223-48.
32. Boire A, Covic L, Agarvai A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloproteinase-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005;120:303-13.
33. Goerge T, Barg A, Schnaeker E-M, et al. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res 2006;66:7766-74.
34. Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in human cancer. Cancer Cell 2003;4:95-8.
35. Nikkola J, Vihinen P, Vuoristo M-S, Kellokumpu-Lehtinen P, Kahari V-M, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005;11:5158-66.
36. Hofmann U, Westphal J, van Muijen G, Ruiter D. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000;115:337-44.
37. Smalley K, Lioni M, Heryln M. Targeting the stromal fibroblasts: a novel approach to melanoma therapy. Expert Rev Anticancer Ther 2005;5:1069-78.
38. Pluda J. Tumor-associated angiogenesis: mechanisms, clinical implications and therapeutic strategies. Semin Oncol 1997;24:203-18.